- Q Bio — a quantitative and clinically-relevant assessment of personal human health — announced it has officially come out of stealth mode and raised $40 million
Q Bio — a quantitative and clinically-relevant assessment of personal human health — announced it has officially come out of stealth mode and raised $40 million in Series B funding led by Andreessen Horowitz. Including this funding round, it brings Q Bio’s total to $58 million. Plus this latest round of funding will enable Q Bio to continue to improve its proprietary platform and technology to make their preventive health services faster, better and more affordable for all.
What does Q Bio do? Q Bio is on a mission to empower people with a deeper understanding of their body and how it’s changing so they have more control over their health. And the company has spent the last few years in stealth mode, focused on fine-tuning its imaging protocols, and determining the most clinically-relevant set of biomarkers to include in its platform that can look for existential risks in an asymptomatic population.
Within 75 minutes, members are able to get a comprehensive picture of their health and receive a web-based dashboard that they can review from anywhere in the world with their chosen clinicians. In late 2019, Q Bio opened up its platform to a limited membership and it is planning to open additional locations this year.
In connection with the funding round, Andreessen Horowitz general partner Vijay Pande will join Q Bio co-founder and CEO Jeffrey Kaditz on the company’s Board of Directors. And Clarissa Shen, who joined in 2019 as Q Bio Chief Operating Officer, will also join as a Board Observer.
Q Bio was founded in 2015 by Kaditz, Dr. Michael Snyder, and Dr. Garry Choy. The company’s investors include Andreessen Horowitz, Khosla Ventures, Founders Fund, Beast Ventures, Thirty5 Venturers, Sea Lane Venturers, and SciFi VC.
“Since my own misdiagnoses over a decade ago, I’ve imagined a day when everything about a person’s body could be quickly measured, shared and analyzed. It took time but Q Bio was born. We are thrilled to have our current investors continue to share our vision and excitement for what is possible in the field of preventive health.”
– Jeffrey Kaditz, co-founder and CEO of Q Bio
“Q Bio makes true preventive medicine possible today. By measuring everything from blood to imaging and more in a longitudinal way, patients can have personalized baselines and physicians the data and power to understand, interpret and utilize this data to personalize care.”
– Vijay Pande, general partner at Andreessen Horowitz